{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:32:09Z","timestamp":1791549129711,"version":"4.3.4"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2018SZ0210"],"award-info":[{"award-number":["2018SZ0210"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2023YFS0488"],"award-info":[{"award-number":["2023YFS0488"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2023YFQ0055"],"award-info":[{"award-number":["2023YFQ0055"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The lymph node ratio (LNR) has emerged as an important prognostic factor in various cancers, including esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the utility of LNR in guiding decisions for adjuvant chemotherapy in ESCC patients following resection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A retrospective analysis was conducted on 2267 patients who underwent potentially curative surgery for ESCC at Sichuan Cancer Hospital and Institute between January 2010 and December 2017. Univariate and multivariate Cox proportional hazards regressions were used to assess factors influencing overall survival (OS), with LNR analyzed using restricted cubic splines (RCS) to explore its relationship with treatment and survival outcomes. Propensity score matching (PSM) was employed to adjust for biases between treatment groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the patients, 1416 underwent surgery alone (S group) and 851 received surgery plus adjuvant chemotherapy (S\u2009+\u2009CT group). The median LNR was 3%, with an interquartile range of 0%-12%. RCS analysis identified an LNR threshold of 11%, below which patients showed a significant OS benefit from adjuvant chemotherapy (hazard ratio [HR]: 0.57; 95% CI: 0.46-0.71; P\u2009&amp;lt;\u20090.001). However, patients with an LNR above 11% did not derive any OS benefit from chemotherapy (HR: 0.87; 95% CI: 0.70-1.09; P\u2009=\u20090.238).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings suggest that LNR is a valuable marker for identifying ESCC patients who would benefit from postoperative adjuvant chemotherapy. A threshold LNR of 11% can help personalize treatment strategies, and patients with higher LNRs may require more intensive approaches like chemoradiotherapy to improve survival. Further prospective studies are needed to validate these results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf315","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:53:42Z","timestamp":1758808422000},"source":"Crossref","is-referenced-by-count":1,"title":["Lymph node ratio predicts adjuvant chemotherapy benefit in esophageal squamous cell carcinoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5732-4899","authenticated-orcid":false,"given":"Jun","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University , Guangzhou, Guangdong, 510060,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center of Suning Central Hospital , Suining, 629000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8834-6801","authenticated-orcid":false,"given":"Xiang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6641-5342","authenticated-orcid":false,"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China , Chengdu, 610041,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2025101712305044600_oyaf315-B1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (cross): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025101712305044600_oyaf315-B2","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025101712305044600_oyaf315-B3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/annonc\/mdr433","article-title":"Esophageal carcinoma advances in treatment results for locally advanced disease: review","volume":"23","author":"Herskovic","year":"2012","journal-title":"Ann Oncol"},{"key":"2025101712305044600_oyaf315-B4","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"2025101712305044600_oyaf315-B5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: Part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"2025101712305044600_oyaf315-B6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12032-014-0417-6","article-title":"Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 cases","volume":"32","author":"Chen","year":"2015","journal-title":"Med Oncol (Northwood, London, England)"},{"key":"2025101712305044600_oyaf315-B7","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1245\/s10434-015-4658-1","article-title":"Impact of adjuvant chemotherapy on patients with lymph node-positive esophageal cancer who are primarily treated with surgery","volume":"22 Suppl 3","author":"Pasquer","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2025101712305044600_oyaf315-B8","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1002\/cam4.5264","article-title":"Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node-positive esophageal squamous cell carcinoma: is oral chemotherapy promising?","volume":"12","author":"Fang","year":"2023","journal-title":"Cancer Med"},{"key":"2025101712305044600_oyaf315-B9","doi-asserted-by":"crossref","first-page":"e2151","DOI":"10.1002\/onco.13914","article-title":"Postoperative adjuvant therapy versus surgery alone for stage IIB-III esophageal squamous cell carcinoma: a phase III randomized controlled trial","volume":"26","author":"Ni","year":"2021","journal-title":"Oncologist"},{"key":"2025101712305044600_oyaf315-B10","doi-asserted-by":"crossref","first-page":"8571438","DOI":"10.1155\/2021\/8571438","article-title":"Postoperative adjuvant therapy for patients with pN+ esophageal squamous cell carcinoma","volume":"2021","author":"Li","year":"2021","journal-title":"Biomed Res Int"},{"key":"2025101712305044600_oyaf315-B11","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1200\/JCO.2003.12.095","article-title":"Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group study\u2014JCOG9204","volume":"21","author":"Ando","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025101712305044600_oyaf315-B12","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.athoracsur.2012.03.078","article-title":"Pathologic lymph node ratio is a predictor of survival in esophageal cancer","volume":"94","author":"Bhamidipati","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"2025101712305044600_oyaf315-B13","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1245\/s10434-012-2794-4","article-title":"The positive lymph node ratio predicts long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China","volume":"20","author":"Hou","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2025101712305044600_oyaf315-B14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jtho.2019.03.027","article-title":"Optimal lymph node examination and adjuvant chemotherapy for Stage I lung cancer","volume":"14","author":"Dai","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025101712305044600_oyaf315-B15","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1245\/s10434-019-07489-3","article-title":"Predicting the value of adjuvant therapy in esophageal squamous cell carcinoma by combining the total number of examined lymph nodes with the positive lymph node ratio","volume":"26","author":"Li","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2025101712305044600_oyaf315-B16","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.21037\/jgo-21-807","article-title":"Impact of postoperative lymph node status on the prognosis of esophageal squamous cell carcinoma after esophagectomy following neoadjuvant chemoradiotherapy: a retrospective study","volume":"12","author":"Sun","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"2025101712305044600_oyaf315-B17","first-page":"55","article-title":"[Efficacy of adjuvant therapy in 110 patients with N1 lymph node metastasis of esophageal squamous cell carcinoma]","volume":"38","author":"Shao","year":"2016","journal-title":"Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]"},{"key":"2025101712305044600_oyaf315-B18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jtho.2017.03.024","article-title":"The impact of postoperative conformal radiotherapy after radical surgery on survival and recurrence in pathologic T3N0M0 esophageal carcinoma: a propensity score-matched analysis","volume":"12","author":"Yang","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025101712305044600_oyaf315-B19","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-019-08112-1","article-title":"Postoperative chemotherapy for thoracic pathological T3N0M0 esophageal squamous cell carcinoma","volume":"27","author":"Wang","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2025101712305044600_oyaf315-B20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/JTO.0000000000000216","article-title":"Can lymph node ratio replace pn categories in the tumor-node-metastasis classification system for esophageal cancer?","volume":"9","author":"Tan","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2025101712305044600_oyaf315-B21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jtho.2016.06.019","article-title":"Assessment of lymph node ratio to replace the pn categories system of classification of the TNM system in esophageal squamous cell carcinoma","volume":"11","author":"Shao","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025101712305044600_oyaf315-B22","first-page":"2087","article-title":"The lymph node ratio is an independent prognostic factor in esophageal cancer patients who receive curative surgery","volume":"34","author":"Yukawa","year":"2020","journal-title":"In Vivo (Athens, Greece)"},{"key":"2025101712305044600_oyaf315-B23","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1245\/s10434-020-09451-0","article-title":"Impact of lymph node ratio on survival outcome in esophageal squamous cell carcinoma after minimally invasive esophagectomy","volume":"28","author":"Kitamura","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2025101712305044600_oyaf315-B24","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1097\/SLA.0000000000004150","article-title":"The relationship between lymph node ratio and survival benefit with adjuvant chemotherapy in node-positive esophageal adenocarcinoma","volume":"275","author":"Raman","year":"2022","journal-title":"Ann Surg"},{"key":"2025101712305044600_oyaf315-B25","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.asjsur.2023.03.160","article-title":"Lymph node ratio precisely predicts the benefit of postoperative radiotherapy in esophageal cancer: a retrospective cohort study","volume":"46","author":"Liang","year":"2023","journal-title":"Asian J Surg"},{"key":"2025101712305044600_oyaf315-B26","doi-asserted-by":"crossref","first-page":"e22600","DOI":"10.1016\/j.heliyon.2023.e22600","article-title":"Positive lymph node ratio is an important index to predict long-term survival for advanced esophageal squamous carcinoma patients (II approximately III) with R0 resection\u2014a SEER-based analysis","volume":"9","author":"Hou","year":"2023","journal-title":"Heliyon"},{"key":"2025101712305044600_oyaf315-B27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/jjco\/hyv206","article-title":"Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy","volume":"46","author":"Duan","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"2025101712305044600_oyaf315-B28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.21147\/j.issn.1000-9604.2017.02.08","article-title":"Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma","volume":"29","author":"Zhang","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"2025101712305044600_oyaf315-B29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1748-717X-8-116","article-title":"Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer","volume":"8","author":"Xu","year":"2013","journal-title":"Radiat Oncol (London, England)"},{"key":"2025101712305044600_oyaf315-B30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/JTO.0b013e318292c53e","article-title":"Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer","volume":"8","author":"Urban","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2025101712305044600_oyaf315-B31","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101712305044600_oyaf315-B32","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2025.43.16_suppl.4000","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577","volume":"43","author":"Kelly","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025101712305044600_oyaf315-B33","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1245\/s10434-025-17332-7","article-title":"Survival impact of adjuvant nivolumab therapy for locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy with docetaxel plus 5-fluorouracil and cisplatin","volume":"32","author":"Sugase","year":"2025","journal-title":"Ann Surg Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf315\/64394588\/oyaf315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf315\/64394588\/oyaf315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf315\/64394588\/oyaf315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:31:01Z","timestamp":1760718661000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf315\/8263832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf315","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,25]]},"article-number":"oyaf315"}}